Literature DB >> 6145488

Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain.

G A Ricaurte, R W Guillery, L S Seiden, C R Schuster, R Y Moore.   

Abstract

Numerous recent studies indicate that when amphetamines are administered continuously or in high doses, they exert long-lasting toxic effects on dopamine (DA) neurons in the central nervous system (CNS). Specifically, it has been shown that amphetamines can decrease the content of brain DA, reduce the number of synaptosomal DA uptake sites and selectively depress the in vitro activity of neostriatal tyrosine hydroxylase (TH). To date, however, anatomical evidence of DA neuronal destruction following amphetamines has not been reported. In this study, chemical methods were used in conjunction with the Fink-Heimer method which allows for the selective silver impregnation of degenerating nerve fibers, in order to determine whether methylamphetamine, a potent psychomotor stimulant often abused by man, causes actual DA neural degeneration. It has been found that methylamphetamine induces terminal degeneration along with correlative DA neurochemical deficits in the neostriatum and nucleus accumbens; furthermore, that in cresyl violet-stained sections of the substantia nigra (SN), pars compacta, and ventral tegmental area (VTA), there is no evidence of cell body loss in rats in which 50-60% of neostriatal DA terminals have been destroyed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6145488     DOI: 10.1016/0006-8993(82)90198-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  120 in total

1.  Biphasic effects of selegiline on striatal dopamine: lack of effect on methamphetamine-induced dopamine depletion.

Authors:  K Grasing; R Azevedo; S Karuppan; S Ghosh
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

2.  Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity.

Authors:  T Xie; U D McCann; S Kim; J Yuan; G A Ricaurte
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

3.  Selective neurotoxins, chemical tools to probe the mind: the first thirty years and beyond.

Authors:  R M Kostrzewa
Journal:  Neurotox Res       Date:  1999-09       Impact factor: 3.911

4.  Neurotoxicity of methamphetamine and methylenedioxymethamphetamine.

Authors:  L S Seiden; R Lew; J E Malberg
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

5.  Synergism between methamphetamine and the neuropeptide substance P on the production of nitric oxide in the striatum of mice.

Authors:  Jing Wang; Jesus A Angulo
Journal:  Brain Res       Date:  2010-11-11       Impact factor: 3.252

Review 6.  Nucleus accumbens invulnerability to methamphetamine neurotoxicity.

Authors:  Donald M Kuhn; Mariana Angoa-Pérez; David M Thomas
Journal:  ILAR J       Date:  2011

7.  5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine.

Authors:  M I Colado; T K Murray; A R Green
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

8.  Lack of effect of kappa-opioid receptor agonism on long-term methamphetamine-induced neurotoxicity in rats.

Authors:  Kamisha L Johnson-Davis; Glen R Hanson; Kristen A Keefe
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

9.  Effect of sulpiride on the amphetamine-induced changes in extracellular dopamine, DOPAC, and hydroxyl radical generation in the rat striatum.

Authors:  Elmira Anderzhanova; Kirill S Rayevsky; Pirjo Saransaari; Simo S Oja
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

10.  Cognitive control and white matter callosal microstructure in methamphetamine-dependent subjects: a diffusion tensor imaging study.

Authors:  Ruth Salo; Thomas E Nordahl; Michael H Buonocore; Yutaka Natsuaki; Christy Waters; Charles D Moore; Gantt P Galloway; Martin H Leamon
Journal:  Biol Psychiatry       Date:  2008-09-23       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.